Yanbo Xu - Publications

Metabolomics Combined With Network Pharmacology to Reveal the Metabolic Differences and Underlying Anti-Inflammatory and Antipyretic Mechanisms of Berchemia lineata.

Journal: Chemistry & biodiversity

Published: February 27, 2026

Feedback regulation between histone H3 lysine 18 lactylation and TROP2-mediated glycolysis drives metastatic progression of colorectal cancer.

Journal: Clinical and translational medicine

Published: August 18, 2025

Tumor-derived lactate promotes resistance to bevacizumab treatment by facilitating autophagy enhancer protein RUBCNL expression through histone H3 lysine 18 lactylation (H3K18la) in colorectal cancer.

Journal: Autophagy

Published: August 24, 2023

The Pathologic Complete Response Ratio of Liver Metastases Represents a Valuable Prognostic Indicator.

Journal: Pathology oncology research : POR

Published: June 21, 2022

DNA ploidy and stroma predicted the risk of recurrence in low-risk stage III colorectal cancer.

Journal: Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico

Published: June 15, 2022

A novel score system for predicting conversion to no evidence of Disease (C-NED) in initially unresectable colorectal cancer liver metastases.

Journal: American journal of cancer research

Published: January 15, 2022

RCC1 Expression as a Prognostic Marker in Colorectal Liver Oligometastases.

Journal: Pathology oncology research : POR

Published: September 13, 2021

Inflammation promotes resistance to immune checkpoint inhibitors in high microsatellite instability colorectal cancer.

Journal: Nature communications

Published: September 12, 2021